Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy

Trial Profile

Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Insulin lispro (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 28 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 04 Apr 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top